Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Niagen Bioscience, Inc.NAGE · Entity 6146 | Director | June 24, 2026 | June 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Niagen Bioscience, Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2036-06-23 | Direct | 31,746 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 31,746 · Balance 31,746 F1: Option vests 100% on June 24, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Option vests 100% on June 24, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 26, 2026 22:02 UTC | Niagen Bioscience, Inc. NAGE · Entity 6146 | GrantStock Option (right to buy) · Derivative | 31,746 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001896252-26-000001 · wk-form4_1782511331.xml · derivative · entry 1 Ng Wang Yu Gary · CIK 0001896252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,746 Underlying: Common Stock · 31,746 shares Expires 2036-06-23 F1 · derivative.exercise_date: Option vests 100% on June 24, 2027. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 00:28 UTC | Niagen Bioscience, Inc. NAGE · Entity 6146 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.13 | $0.00 |
DisclosureSEC source: 0001628280-25-033061 · wk-form4_1750897677.xml · derivative · entry 1 Ng Wang Yu Gary · CIK 0001896252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-06-23 F1 · derivative.exercise_date: Option vests 100% on June 24, 2026. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 21:43 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.71 | $0.00 |
DisclosureSEC source: 0001628280-24-029650 · wk-form4_1719265412.xml · derivative · entry 1 Ng Wang Yu Gary · CIK 0001896252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: Option vests 100% on June 20, 2025. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 21:25 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001628280-23-022530 · wk-form4_1686950733.xml · derivative · entry 1 Ng Wang Yu Gary · CIK 0001896252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: Option vests 100% on June 15, 2024. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 22:22 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001628280-22-017713 · wf-form4_165585011423542.xml · derivative · entry 1 Ng Wang Yu Gary · CIK 0001896252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: Option vests 100% on June 16, 2023. Read SEC document |
| December 13, 2021 Filed Dec 14, 2021 23:06 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.24 | $0.00 |
DisclosureSEC source: 0001628280-21-025061 · wf-form4_163952319561269.xml · derivative · entry 1 Ng Wang Yu Gary · CIK 0001896252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-12-12 F1 · derivative.exercise_date: The option vests in three substantially equal annual installments beginning on December 13, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.